Vaxcyte, Inc. PCVX
Set alert
62.03 USD -0.58 -0.93%
At close · Oct 30
61.99 -0.04 -0.06%
After hours · Oct 30, 6:40 PM ET
61.02 Day range 63.28
40.32 52-week range 73.82
- YTD
- +34.44%
- 1 year
- +38.61%
- Open
- 62.59
- Prev close
- 62.61
- Mkt cap
- 9.76B
- Vol
- 1.71M
- Avg vol
- 2.06M
- EPS
- -7.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 61.02
- High
- 63.28
- Forward P/E
- -8.71
- Beta
- 1.23
- Short ratio
- 4.40
- Inst. own
- 111.05%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 61.59
- 200-d avg
- 56.97
- 1y target
- 117.30
2Y chart
Events in this range
- Aug 6, 2025Earnings: -1.22; estimate -1.12; surprise -8.93%
- Nov 4, 2025Earnings: -1.56; estimate -1.27; surprise -22.83%
- Feb 24, 2026Earnings: -1.8; estimate -1.52973; surprise -17.67%
- May 6, 2026Earnings: -2.3; estimate -1.7775; surprise -29.4%
- Aug 5, 2026Earnings: -1.97; estimate -2.06; surprise 4.37%
- Sep 25, 2026Rating: Needham · Buy → Buy
- Sep 28, 2026Rating: B of A Securities · Buy → Buy
- Oct 5, 2026Rating: Guggenheim · Buy → Buy
- Oct 5, 2026Rating: Needham · Buy → Buy
- Oct 5, 2026Rating: BTIG · Buy → Buy
- Oct 12, 2026Rating: Cantor Fitzgerald · Overweight → Overweight
Signals (89)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 29, 2026 | 2 days ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 19, 2026 | 1 week ago |
| SMA: Bullish | Oct 5, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 5, 2026 | 3 weeks ago |
| RSI: Overbought | Oct 5, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 15, 2026 | 3 months ago |
| RSI: Overbought | Jun 30, 2026 | 4 months ago |
| SMA: Bullish | Jun 24, 2026 | 4 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| SMA: Bullish | Jun 4, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 4, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 3, 2026 | 5 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| MACD: Buy Signal | May 29, 2026 | 5 months ago |
| SMA: Bullish | May 26, 2026 | 5 months ago |
| SMA: Bearish | May 20, 2026 | 5 months ago |
| RSI: Oversold | May 20, 2026 | 5 months ago |
| RSI: Oversold | May 18, 2026 | 5 months ago |
| SMA: Bearish | Apr 29, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 23, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 1, 2026 | 7 months ago |
| SMA: Bullish | Mar 31, 2026 | 7 months ago |
| SMA: Bearish | Mar 26, 2026 | 7 months ago |
| SMA: Bullish | Mar 25, 2026 | 7 months ago |
| SMA: Bearish | Mar 24, 2026 | 7 months ago |
| SMA: Bullish | Mar 23, 2026 | 7 months ago |
| SMA: Bearish | Mar 18, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 5, 2026 | 8 months ago |
| RSI: Overbought | Feb 24, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 20, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 12, 2026 | 8 months ago |
| RSI: Overbought | Feb 2, 2026 | 9 months ago |
| RSI: Overbought | Jan 22, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 14, 2026 | 9 months ago |
| SMA: Bullish | Jan 9, 2026 | 9 months ago |
| SMA: Bearish | Jan 8, 2026 | 9 months ago |
| SMA: Bullish | Jan 7, 2026 | 9 months ago |
| SMA: Bearish | Jan 6, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 5, 2026 | 9 months ago |
| MACD: Buy Signal | Dec 23, 2025 | 10 months ago |
| SMA: Bullish | Dec 19, 2025 | 10 months ago |
| SMA: Bearish | Dec 10, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 1, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 13, 2025 | 11 months ago |
| SMA: Bullish | Nov 11, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 21, 2025 | 1 year ago |
| RSI: Overbought | Oct 15, 2025 | 1 year ago |
| RSI: Overbought | Oct 9, 2025 | 1 year ago |
| RSI: Overbought | Oct 1, 2025 | 1 year ago |
| SMA: Bullish | Sep 26, 2025 | 1 year ago |
| SMA: Bearish | Sep 25, 2025 | 1 year ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 18, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 17, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 29, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 26, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 21, 2025 | 1 year ago |
| RSI: Oversold | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Jul 31, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 29, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 9, 2025 | 1 year ago |
| SMA: Bullish | Jul 8, 2025 | 1 year ago |
| SMA: Bearish | Jun 26, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 20, 2025 | 1 year ago |
| SMA: Bullish | Jun 5, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 17, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 31, 2025 | 1 year ago |
| RSI: Oversold | Mar 31, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 14, 2025 | 1 year ago |
| RSI: Oversold | Feb 28, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 10, 2025 | 1 year ago |
| SMA: Bearish | Feb 7, 2025 | 1 year ago |
| SMA: Bullish | Feb 5, 2025 | 1 year ago |
| SMA: Bearish | Feb 3, 2025 | 1 year ago |
| SMA: Bullish | Jan 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 15, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 14, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 3, 2025 | 1 year ago |
| MACD: Sell Signal | Dec 27, 2024 | 1 year ago |
| RSI: Oversold | Dec 27, 2024 | 1 year ago |
Key statistics
- Market cap
- 9.76B
- Enterprise value
- 7.95B
- Trailing P/E
- 0.00
- Forward P/E
- -8.71
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.26
- EPS (TTM)
- -7.62
- Beta
- 1.23
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -485.76M
- Total cash
- 1.49B
- Total debt
- 115.44M
- Return on equity
- -36.51%
- Shares outstanding
- 157.39M
- Short % of float
- 9.34%
- 50-day average
- 61.59
- 200-day average
- 56.97
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 117.30 +89.1% upside
Now 62.03
- Target (low)
- 75.00
- Target (mean)
- 117.30
- Target (high)
- 163.00
Ratings (0m) 11 10 buy · 1 hold · 0 sell
- Strong buy1
- Buy9
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate -2.11.
Financials — quick view
PCVX Revenue — quarterly 0
PCVX Net income — quarterly -284.30M
PCVX EPS — quarterly -1.97
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -2.11 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | -2.06 | -1.97 | +0.09 | +4.37% |
| May 6, 2026 | Mar 31, 2026 | -1.78 | -2.30 | -0.52 | -29.40% |
| Feb 24, 2026 | Dec 31, 2025 | -1.53 | -1.80 | -0.27 | -17.67% |
| Nov 4, 2025 | Sep 30, 2025 | -1.27 | -1.56 | -0.29 | -22.83% |
| Aug 6, 2025 | Jun 30, 2025 | -1.12 | -1.22 | -0.10 | -8.93% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Oct 5, 2026 | BTIG | reit | Buy | Buy |
| Oct 5, 2026 | Needham | main | Buy | Buy |
| Oct 5, 2026 | Guggenheim | main | Buy | Buy |
| Sep 28, 2026 | B of A Securities | main | Buy | Buy |
| Sep 25, 2026 | Needham | reit | Buy | Buy |
About Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vaxcyte.com
News
- Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?
- Vaxcyte, Inc. (NASDAQ:PCVX) Stock Rated “Moderate Buy” by Sell-Side Brokerages
- Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet
- Cantor Fitzgerald Reiterates Overweight on Vaxcyte, Announces $120 Price Target
- Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'
- Vaxcyte (NASDAQ: PCVX) raises $575 million with notes and stock sale
- A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
- Vaxcyte (NASDAQ:PCVX) EVP Jim Wassil Sells 18,000 Shares of Company Stock
- Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
- Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027
Your note
Sign in to keep a note on PCVX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COWAN ELVIA | Officer | Sale | Oct 4, 2026 | 27,860 |
| DHALIWAL HARPREET S. | Officer | Sale | Aug 4, 2026 | 76,756 |
| EYDELMAN MIKHAIL | General Counsel | Sale | Mar 4, 2025 | 41,620 |
| GUGGENHIME ANDREW | President | Sale | Aug 2, 2026 | 167,026 |
| JODAR LUIS | Officer | Stock Award(Grant) | Sep 3, 2026 | 52,632 |
| LOXAM TERI | Director | Stock Award(Grant) | Jun 14, 2026 | 12,481 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.01% | 20,852,907 | 1.29B | Jun 29, 2026 |
| Jupiter Topco LLC | 12.07% | 17,965,847 | 1.11B | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 8.20% | 12,207,450 | 757.23M | Jun 29, 2026 |
| Blackrock Inc. | 8.11% | 12,068,129 | 748.59M | Jun 29, 2026 |
| RA Capital Management, L.P. | 7.71% | 11,474,599 | 711.77M | Jun 29, 2026 |
| Wellington Management Group, LLP | 4.71% | 7,001,565 | 434.31M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.08% | 4,587,918 | 284.59M | Jun 29, 2026 |
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 2.69% | 4,007,229 | 248.57M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.29% | 3,411,349 | 211.61M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.23% | 3,312,950 | 205.50M | Jun 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 2.11% | 3,145,705 | 195.13M | Aug 30, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Forty Fund | 1.80% | 2,676,774 | 166.04M | Jun 29, 2026 |